Frequent Urination / Urinary Incontinence - Takeda and Toray to Develop Investigational Compound
Main Category: Urology / NephrologyArticle Date: 07 Apr 2005 - 12:00 PDT
'Frequent Urination / Urinary Incontinence - Takeda and Toray to Develop Investigational Compound'
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Tokyo (JCNN) - Takeda Pharmaceutical (TSE: 4502) and Toray Industries (TSE: 3402) announced today that the companies have concluded a joint development and marketing agreement on an investigational compound for frequent urination/urinary incontinence.
Under the terms of the agreement, Takeda and Toray will jointly develop the compound, while Toray will market in Japan and Takeda will market overseas. The partners hope this collaboration will enable the efficient development processes and the earliest possible commercialization of this compound.
The compound is now in the preparation stage for Phase I studies in the U.S.
The compound, with development codes of TRK-130 for Toray and TAK-363 for Takeda, was found in Toray's compound library as a potential treatment for such diseases, through joint research by both parties started in June 2000.
Frequent urination and urinary incontinence are mostly seen as the symptoms of the overactive bladder (OAB) with increased patients in line with aging, and affect the quality of life (QOL) remarkably because the daily lifestyle habits such as the nighttime sleep or transportation are disturbed.
Presently, symptoms are treated with anticholinergic agents which are known to have side effects such as dry mouth, constant urge to urinate and constipation. Based on the findings to date, this compound has different mechanism of action to suppress the bladder hypersensitivity with high selectivity, and is expected to have lesser side effects which can be seen with the treatment by anticholinergic agents.
Therefore, the new compound can be a treatment option with a new action mechanism for frequent urination and urinary incontinence, contributing to improvement of the QOL of the patients.
View Takeda Pharmaceutical Company, Ltd. company profile here
Copyright © 2001-2004 JCNN. All rights reserved. A division of Japan Corporate News Network KK.
Visit our urology / nephrology section for the latest news on this subject.
MLA
26 May. 2012. <http://www.medicalnewstoday.com/releases/22473.php>
APA
http://www.medicalnewstoday.com/releases/22473.php.
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'Frequent Urination / Urinary Incontinence - Takeda and Toray to Develop Investigational Compound'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




